8-KRegulation FDOther EventsExhibits & Filings

CARDINAL HEALTH INC 8-K Report, Regulation FD Disclosure (Jun 9, 2009)

Filed June 9, 2009For Securities:CAH

Summary

This 8-K filing from Cardinal Health Inc. (CAH) on June 9, 2009, primarily focuses on disclosures related to the planned spin-off of its clinical and medical products businesses into a new entity, CareFusion Corporation. Investors should note that CareFusion has filed a second amendment to its Form 10 registration statement, which includes details on its expected board of directors and progress in complying with an Amended Consent Decree with the FDA. This is a significant step in the process towards CareFusion becoming a publicly traded company, and investors considering the spin-off should pay close attention to these developments. The filing also provides an update on Cardinal Health's compliance with the Amended Consent Decree with the FDA. The FDA has accepted the company's corrective action plan, and an independent expert has provided certifications related to the conformity of its operations with the Federal Food, Drug and Cosmetic Act. These approvals are crucial for regulatory compliance and demonstrate progress in resolving past issues, which is positive for the overall health of the business, including the divested entity.

Key Highlights

  • 1CareFusion Corporation, the entity for the planned spin-off of Cardinal Health's clinical and medical products businesses, filed a second amendment to its Form 10 registration statement.
  • 2The CareFusion Form 10 amendment includes the names of individuals expected to join CareFusion's board of directors.
  • 3The filing details CareFusion's progress in complying with the Amended Consent Decree between a Cardinal Health subsidiary and the U.S. Food and Drug Administration (FDA).
  • 4The FDA has accepted Cardinal Health's corrective action plan required by the Amended Consent Decree.
  • 5The FDA notified Cardinal Health on June 2, 2009, that the corrective action plan was acceptable and implementation should begin.
  • 6An independent expert provided a final certification to the FDA on June 2, 2009, covering the remaining items required by the Amended Consent Decree.
  • 7The filing serves as a Regulation FD disclosure for the information concerning CareFusion's progress and FDA compliance.

Frequently Asked Questions